<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166963">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00924118</url>
  </required_header>
  <id_info>
    <org_study_id>00023049</org_study_id>
    <nct_id>NCT00924118</nct_id>
  </id_info>
  <brief_title>Sodium Nitrite in Acute Myocardial Infarction</brief_title>
  <official_title>A Safety and Efficacy Evaluation of Sodium Nitrite Injection for the Prevention of Ischemia-Reperfusion Injury Associated With Acute Myocardial Infarction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hope Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the intravenous infusion of sodium nitrite
      safely prevents ischemia-reperfusion injury in subjects with acute myocardial infarction
      resulting in improved left ventricular function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite reperfusion therapies, significant myocardial injury continues to occur from
      ischemic-reperfusion injury. Studies in animal models of acute myocardial infarction suggest
      that an infusion of sodium nitrite, which is nonenzymatically converted to nitric oxide in
      the setting of ischemia, significantly reduces ischemia-reperfusion injury resulting in
      smaller infarcts and improved left ventricular function. The objectives of this phase 2
      trial are to determine the tolerability and safety of a 48-hour infusion of sodium nitrite
      in patients with an acute ST-segment elevation myocardial infarction receiving percutaneous
      coronary intervention. The efficacy of a 48-hour infusion of sodium nitrite will be
      determined by noninvasive imaging to determine infarct size and left ventricular function.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary efficacy outcome is a to determine whether sodium nitrite safely reduces infarct size normalized for the ischemia area at risk as determined by paired single-photon computed tomography studies with technetium Tc99m sestamibi.</measure>
    <time_frame>4-5 days from enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular volumes, ejection fraction, and infarct size by magnetic resonance imaging.</measure>
    <time_frame>4-5 days following enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Sodium Nitrite</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of sodium nitrite.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects randomized to open control will receive no experimental therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Nitrite</intervention_name>
    <description>Subjects assigned to sodium nitrite will receive an initial infusion of 6 nmol/min/kg for 48 hours. After the first six subjects have been enrolled (3 active drug, 3 control) and if there are no dose limiting toxicities, additional cohorts of six subjects each will be randomized to escalating doses of sodium nitrite versus control for a total of 30 subjects.</description>
    <arm_group_label>Sodium Nitrite</arm_group_label>
    <other_name>None available</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute ST segment elevation myocardial infarction

          -  Eligible for percutaneous coronary intervention

        Exclusion Criteria:

          -  Cardiogenic shock

          -  Cardiac arrest

          -  Prior infarct in the infarct related artery

          -  Hemoglobinopathy, GG6PD deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven P Schulman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven P Schulman, MD</last_name>
    <phone>410-955-7378</phone>
    <email>sschulma@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeffrey R Rade, MD</last_name>
    <phone>508-334-3452</phone>
    <email>Jeffrey.Rade@umassmed.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven P Schulman, MD</last_name>
      <phone>410-955-7378</phone>
      <email>sschulma@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Steven P Schulman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gonzalez FM, Shiva S, Vincent PS, Ringwood LA, Hsu LY, Hon YY, Aletras AH, Cannon RO 3rd, Gladwin MT, Arai AE. Nitrite anion provides potent cytoprotective and antiapoptotic effects as adjunctive therapy to reperfusion for acute myocardial infarction. Circulation. 2008 Jun 10;117(23):2986-94. doi: 10.1161/CIRCULATIONAHA.107.748814. Epub 2008 Jun 2.</citation>
    <PMID>18519850</PMID>
  </reference>
  <reference>
    <citation>Duranski MR, Greer JJ, Dejam A, Jaganmohan S, Hogg N, Langston W, Patel RP, Yet SF, Wang X, Kevil CG, Gladwin MT, Lefer DJ. Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. J Clin Invest. 2005 May;115(5):1232-40. Epub 2005 Apr 14.</citation>
    <PMID>15841216</PMID>
  </reference>
  <reference>
    <citation>Rassaf T, Fl√∂gel U, Drexhage C, Hendgen-Cotta U, Kelm M, Schrader J. Nitrite reductase function of deoxymyoglobin: oxygen sensor and regulator of cardiac energetics and function. Circ Res. 2007 Jun 22;100(12):1749-54. Epub 2007 May 10.</citation>
    <PMID>17495223</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 24, 2016</lastchanged_date>
  <firstreceived_date>June 17, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Steven P. Schulman, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Acute myocardial infarction</keyword>
  <keyword>Reperfusion injury</keyword>
  <keyword>Nitric oxide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
